First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

20171,141 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 389, Issue 10072, pp. 917-929

Field-Weighted Citation Impact: 112.11